13 Best Low Priced Pharma Stocks to Buy Now

6. Viridian Therapeutics Inc. (NASDAQ:VRDN)

Share Price as of July 14: $17.14

Number of Hedge Fund Holders: 40

Viridian Therapeutics Inc. (NASDAQ:VRDN) is one of the best low priced pharma stocks to buy now. Earlier on May 20, Viridian Therapeutics announced positive long-term durability data from its Phase 3 THRIVE clinical trial of veligrotug (“veli”). Veligrotug is an intravenously delivered anti-insulin-like growth factor-1 receptor (IGF-1R) antibody being developed for active thyroid eye disease/TED, which is an autoimmune condition that causes inflammation, growth, and damage to tissues around and behind the eye.

The THRIVE Phase 3 clinical trial in active TED evaluated 5 infusions of veligrotug or placebo administered every 3 weeks, with the primary topline analysis conducted at week 15, and patients followed through week 52. The new data reveal strong durability: 70% (21 out of 30) of veligrotug-treated patients in THRIVE who were proptosis responders at week 15 and continued follow-up to week 52, maintained their proptosis response.

The safety profile remained consistent during the follow-up period, with the vast majority of adverse events reported at the week 15 primary analysis having resolved by week 52. Veligrotug recently received Breakthrough Therapy Designation/BTD from the FDA, which supports its eligibility for Priority Review.

Viridian Therapeutics Inc. (NASDAQ:VRDN) discovers, develops, and commercializes treatments for serious and rare diseases.